

**ASX ANNOUNCEMENT**

**\$711K R&D TAX CREDIT RECEIVED**

**SYDNEY, Friday, 04 October 2013: Cellmid Limited (ASX: CDY)** advises that it has received \$711,895.35 refund under the Federal Government's R&D Tax Incentive Scheme.

The tax refund relates to the cost of research and development conducted by the Company on its midkine technology portfolio during the 2013 financial year and was calculated as 45% of eligible expenditure.

A further \$42,157 is expected in the coming weeks in relation to qualifying research and development activity in the Company's subsidiary, Advangen International Pty Ltd.

The funds will be used to advance Cellmid's product development programmes.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au).

**Midkine (MK)**

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.